Nouhad Husseini
Director/Board Member bij DECIBEL THERAPEUTICS, INC.
Profiel
Nouhad Husseini is currently the Director & Managing Director at Checkmate Pharmaceuticals, Inc. and Decibel Therapeutics, Inc. He also holds the position of Senior VP-Business Development at Regeneron Pharmaceuticals, Inc. Husseini completed his undergraduate degree at Princeton University and obtained an MBA from The Wharton School of the University of Pennsylvania.
Actieve functies van Nouhad Husseini
| Bedrijven | Functie | Begin |
|---|---|---|
| REGENERON PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01-01-2011 |
| CHECKMATE PHARMACEUTICALS, INC. | Director/Board Member | 31-05-2022 |
| DECIBEL THERAPEUTICS, INC. | Director/Board Member | 22-09-2023 |
Opleiding van Nouhad Husseini
| Princeton University | Undergraduate Degree |
| The Wharton School of the University of Pennsylvania | Masters Business Admin |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 2 |
|---|---|
| REGENERON PHARMACEUTICALS, INC. | Health Technology |
| DECIBEL THERAPEUTICS, INC. | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
Checkmate Pharmaceuticals, Inc.
 Checkmate Pharmaceuticals, Inc. BiotechnologyHealth Technology Checkmate Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in developing and commercializing proprietary technology to harness the power of the immune system to combat cancer. The firm's product candidate, vidutolimod is a differentiated TLR9 agonist delivered as a biologic virus-like particle designed to trigger the body's innate immune system to attack tumors in combination with other therapies. The company was founded by Arthur M. Krieg and Chuck Yo in July 2015 and is headquartered in Cambridge, MA. | Health Technology |
